BACKGROUND: Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic hematopoietic stem cell transplantation. Results were derived from heterogeneous, small populations and their value remains a matter of debate. DESIGN AND METHODS: In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin 1 receptor antagonist (IL1RN), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), interferon (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia. Three good predictors of overall survival, identified via statistical methods including Cox regression analysis, were investigated for their effects on transplant-related mortality and relapse. Predictive power was assessed after integration into the established European Group for Blood and Marrow Transplantation (EBMT) risk score. RESULTS: Absence of patient TNFRSFIB 196R, absence of donor IL10 ATA/ACC and presence of donor IL1RN allele 2 genotypes were associated with increased transplantation-related mortality and decreased survival. Application of prediction error and concordance index statistics gave evidence that integration improved the EBMT risk score. CONCLUSIONS: Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell transplantation. When three genetic polymorphisms were added into the EBMT risk model they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell transplantation.
BACKGROUND: Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic hematopoietic stem cell transplantation. Results were derived from heterogeneous, small populations and their value remains a matter of debate. DESIGN AND METHODS: In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin 1 receptor antagonist (IL1RN), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), interferon (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia. Three good predictors of overall survival, identified via statistical methods including Cox regression analysis, were investigated for their effects on transplant-related mortality and relapse. Predictive power was assessed after integration into the established European Group for Blood and Marrow Transplantation (EBMT) risk score. RESULTS: Absence of patient TNFRSFIB 196R, absence of donorIL10 ATA/ACC and presence of donorIL1RN allele 2 genotypes were associated with increased transplantation-related mortality and decreased survival. Application of prediction error and concordance index statistics gave evidence that integration improved the EBMT risk score. CONCLUSIONS: Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell transplantation. When three genetic polymorphisms were added into the EBMT risk model they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell transplantation.
Authors: Gail L Stark; Anne M Dickinson; Graham H Jackson; Penelope R Taylor; Stephen J Proctor; Peter G Middleton Journal: Transplantation Date: 2003-12-27 Impact factor: 4.939
Authors: B Speck; M M Bortin; R Champlin; J M Goldman; R H Herzig; P B McGlave; H A Messner; R S Weiner; A A Rimm Journal: Lancet Date: 1984-03-24 Impact factor: 79.321
Authors: P G Middleton; J Norden; H Cullup; J Cavet; G H Jackson; P R A Taylor; A M Dickinson Journal: Bone Marrow Transplant Date: 2003-07 Impact factor: 5.483
Authors: Leigh J Keen; Todd E DeFor; Jeffrey L Bidwell; Stella M Davies; Benjamin A Bradley; Jill M Hows Journal: Blood Date: 2003-12-30 Impact factor: 22.113
Authors: Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker Journal: N Engl J Med Date: 2003-03-13 Impact factor: 91.245
Authors: Daniel J DeAngelo; Ephraim P Hochberg; Edwin P Alyea; Janina Longtine; Stephanie Lee; Ilene Galinsky; Ben Parekkedon; Jerome Ritz; Joseph H Antin; Richard M Stone; Robert J Soiffer Journal: Clin Cancer Res Date: 2004-08-01 Impact factor: 12.531
Authors: Kim F Pearce; Stephanie J Lee; Michael Haagenson; Effie W Petersdorf; Jean Norden; Matthew P Collin; John P Klein; Stephen R Spellman; Shelagh A Lowerson; Stella Davies; Anne M Dickinson Journal: Haematologica Date: 2012-01-22 Impact factor: 9.941
Authors: Y Balavarca; K Pearce; J Norden; M Collin; G Jackson; E Holler; R Dressel; H-J Kolb; H Greinix; G Socie; A Toubert; V Rocha; E Gluckman; I Hromadnikova; P Sedlacek; D Wolff; U Holtick; A Dickinson; H Bickeböller Journal: Bone Marrow Transplant Date: 2015-07-27 Impact factor: 5.483
Authors: Mark G J de Boer; Hetty Jolink; Constantijn J M Halkes; Pim L J van der Heiden; Dennis Kremer; J H Frederik Falkenburg; Esther van de Vosse; Jaap T van Dissel Journal: PLoS One Date: 2011-04-04 Impact factor: 3.240
Authors: Rihab Gam; Pranali Shah; Rachel E Crossland; Jean Norden; Anne M Dickinson; Ralf Dressel Journal: Front Immunol Date: 2017-04-03 Impact factor: 7.561
Authors: P G Vaughan-Shaw; F O'Sullivan; S M Farrington; E Theodoratou; H Campbell; M G Dunlop; L Zgaga Journal: Br J Cancer Date: 2017-03-16 Impact factor: 7.640